International Psoriasis Council
Advancing Knowledge. Improving Care.
WELCOME + INTRODUCTION
George Sorin Tiplica
Psoriasis: From Pathophysiology to Targeted Therapy
Wolf Henning Boehncke
Phenotypes of Psoriasis
Peter van de Kerkhof
Comorbidities of Psoriasis
Luigi Naldi
Psoriasis: Treat to Target
Ulrich Mrowietz
CLOSING COMMENTS
Lluís Puig
WELCOME + INTRODUCTION
Lluís Puig
Psoriasis: Assessment of Disease Severity in Clinical Practice
Marcus Schmitt-Egenolf
Optimizing Use of Topical Therapy and Conventional Systemic Agents in Psoriasis
Peter van de Kerkhof
Psoriatic Arthritis: Early Diagnosis and Management
Alice Gottlieb
Management of Pustular Psoriasis
Hervé Bachelez
Global Psoriasis Atlas
Darren Ashcroft
CLOSING COMMENTS
George Sorin Tiplica
WELCOME + INTRODUCTION
George-Sorin Tiplica
Psoriasis in Special Areas (Palms and Soles, Nails, Scalp, Genital Areas)
George-Sorin Tiplica
Management of Erythrodermic Psoriasis
Deepak Balak
Role of Phototherapy in the Management of Psoriasis
Mohamed El-Komy
Lifestyle & Psoriasis
Jörg Prinz
Optimizing the Use of Biologics and Biosimilars in Psoriasis
Arnon Cohen
CLOSING COMMENTS
Lluís Puig
WELCOME + INTRODUCTION
George-Sorin Tiplica
Management of Psoriasis in Children
Carmen Salavastru
Management of Psoriasis in Pregnant and Breastfeeding Women
Mahira Hamdy El Sayed
CHALLENGING PSORIASIS CASE WORKSHOP – FACULTY
Case 1: Recalcitrant Psoriasis in Obesity
Adelina Sendrea
Case 2: Psoriasis with Hep B
TBD
Case 3: Patients with Strong FH of Malignancy, Personal History of Lymphoma or Breast Cancers
Marijana Vičić
Case 4: Patient with Tuberculosis and Psoriasis
Filip Rob
CLOSING COMMENTS
Lluís Puig
WELCOME + INTRODUCTION
Lluís Puig
Impact of the COVID-19 Pandemic on Management of Psoriasis; Role of Teledermatology
Alba Català
New and Emerging Therapy for Psoriasis
Lluís Puig
Role of Patient Support Groups in Psoriasis
Josef de Guzman
CHALLENGING PSORIASIS CASE WORKSHOP – PRESENTED BY DELEGATES
CLOSING COMMENTS
George-Sorin Tiplica and Lluís Puig
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
